Dapagliflozin for the treatment of type 1 diabetes mellitus. (3rd July 2017)

• Record Type: Journal Article
• Authors: Pafili, Kalliopi; Maltezos, Efstratios; Papanas, Nikolaos
• Is Part Of: Expert opinion on investigational drugs. Volume 26:Number 7(2017)
• Page Start: 873
• Page End: 881
• Publication Date: 2017-07-03
• Subjects: Dapagliflozin -- SGLT2 inhibitors -- treatment -- type 1 diabetes mellitus -- untoward effects; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2017.1339788
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : In 2017, the management of type 1 diabetes mellitus (T1DM) remains intriguing for the clinician, who has to balance between adequate glycemic control and untoward events related to insulin up-titration. Thus, agents that will complement insulin actions and reduce adverse effects are highly welcome. Areas covered : In this review, the authors summarize results from studies on the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin in T1DM. Expert opinion : In T1DM, dapagliflozin is associated with significant antihyperglycemic and metabolic properties, which are achieved with reduction or stabilization of insulin dose and with a very low trend for hypoglycemia. However, there is a lot to learn with respect to diabetic ketoacidosis (DKA), bone fractures and lower limb ischemia.